438 related articles for article (PubMed ID: 27365459)
21. Immunotherapy of Hodgkin Lymphoma: Mobilizing the Patient's Immune Response.
Ansell SM
Cancer J; 2018; 24(5):249-253. PubMed ID: 30247261
[TBL] [Abstract][Full Text] [Related]
22. Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma.
Calabretta E; d'Amore F; Carlo-Stella C
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31694167
[TBL] [Abstract][Full Text] [Related]
23. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.
Liu WR; Shipp MA
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):310-316. PubMed ID: 29222272
[TBL] [Abstract][Full Text] [Related]
24. Novel agents in the treatment of Hodgkin lymphoma: Biological basis and clinical results.
Younes A; Ansell SM
Semin Hematol; 2016 Jul; 53(3):186-9. PubMed ID: 27496310
[TBL] [Abstract][Full Text] [Related]
25. Classical Hodgkin lymphoma cells may promote an IL-17-enriched microenvironment.
Ferrarini I; Rigo A; Zamò A; Vinante F
Leuk Lymphoma; 2019 Dec; 60(14):3395-3405. PubMed ID: 31304817
[TBL] [Abstract][Full Text] [Related]
26. Targeting immune checkpoints in lymphoma.
Ansell SM
Curr Opin Hematol; 2015 Jul; 22(4):337-42. PubMed ID: 26049755
[TBL] [Abstract][Full Text] [Related]
27. Potential role of hypoxia in early stages of Hodgkin lymphoma pathogenesis.
Wein F; Otto T; Lambertz P; Fandrey J; Hansmann ML; Küppers R
Haematologica; 2015 Oct; 100(10):1320-6. PubMed ID: 26160878
[TBL] [Abstract][Full Text] [Related]
28. Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1.
Reinke S; Bröckelmann PJ; Iaccarino I; Garcia-Marquez M; Borchmann S; Jochims F; Kotrova M; Pal K; Brüggemann M; Hartmann E; Sasse S; Kobe C; Mathas S; Soekler M; Keller U; Bormann M; Zimmermann A; Richter J; Fuchs M; von Tresckow B; Borchmann P; Schlößer H; von Bergwelt-Baildon M; Rosenwald A; Engert A; Klapper W
Blood; 2020 Dec; 136(25):2851-2863. PubMed ID: 33113552
[TBL] [Abstract][Full Text] [Related]
29. Constitutive overexpression of a novel 21 kDa protein by Hodgkin lymphoma and aggressive non-Hodgkin lymphomas.
Zhou M; Fadlelmola FM; Cohn JB; Skinnider B; Gascoyne RD; Banerjee D
Mol Cancer; 2008 Jan; 7():12. PubMed ID: 18218123
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma.
Gribben JG; Fowler N; Morschhauser F
J Clin Oncol; 2015 Sep; 33(25):2803-11. PubMed ID: 26195701
[TBL] [Abstract][Full Text] [Related]
31. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome.
Chetaille B; Bertucci F; Finetti P; Esterni B; Stamatoullas A; Picquenot JM; Copin MC; Morschhauser F; Casasnovas O; Petrella T; Molina T; Vekhoff A; Feugier P; Bouabdallah R; Birnbaum D; Olive D; Xerri L
Blood; 2009 Mar; 113(12):2765-3775. PubMed ID: 19096012
[TBL] [Abstract][Full Text] [Related]
32. Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma.
Aoki T; Chong LC; Takata K; Milne K; Marshall A; Chavez EA; Miyata-Takata T; Ben-Neriah S; Unrau D; Telenius A; Boyle M; Weng AP; Savage KJ; Scott DW; Farinha P; Shah SP; Nelson BH; Steidl C
Proc Natl Acad Sci U S A; 2021 Oct; 118(41):. PubMed ID: 34615710
[TBL] [Abstract][Full Text] [Related]
33. Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment.
Carbone A; Gloghini A; Castagna L; Santoro A; Carlo-Stella C
J Pathol; 2015 Sep; 237(1):4-13. PubMed ID: 25953622
[TBL] [Abstract][Full Text] [Related]
34. [Pathology of Hodgkin's lymphoma].
Hansmann ML; Willenbrock K
Verh Dtsch Ges Pathol; 2003; 87():53-7. PubMed ID: 16888894
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies.
Tun AM; Ansell SM
Cancer Treat Rev; 2020 Aug; 88():102042. PubMed ID: 32521386
[TBL] [Abstract][Full Text] [Related]
36. Follicular peripheral T-cell lymphoma expands the spectrum of classical Hodgkin lymphoma mimics.
Moroch J; Copie-Bergman C; de Leval L; Plonquet A; Martin-Garcia N; Delfau-Larue MH; Molinier-Frenkel V; Belhadj K; Haioun C; Audouin J; Swerdlow SH; Marafioti T; Gaulard P
Am J Surg Pathol; 2012 Nov; 36(11):1636-46. PubMed ID: 23073322
[TBL] [Abstract][Full Text] [Related]
37. Mass cytometry of Hodgkin lymphoma reveals a CD4
Cader FZ; Schackmann RCJ; Hu X; Wienand K; Redd R; Chapuy B; Ouyang J; Paul N; Gjini E; Lipschitz M; Armand P; Wu D; Fromm JR; Neuberg D; Liu XS; Rodig SJ; Shipp MA
Blood; 2018 Aug; 132(8):825-836. PubMed ID: 29880615
[TBL] [Abstract][Full Text] [Related]
38. Checkpoint Inhibition in Hodgkin Lymphoma: Saving the Best for Last?
Lin RJ; Diefenbach CS
Oncology (Williston Park); 2016 Oct; 30(10):914-20. PubMed ID: 27753058
[TBL] [Abstract][Full Text] [Related]
39. Novel agents in the therapy of Hodgkin lymphoma.
Ansell S
Am Soc Clin Oncol Educ Book; 2015; ():e479-82. PubMed ID: 25993212
[TBL] [Abstract][Full Text] [Related]
40. Reed-Sternberg-Like Cells in Non-Hodgkin Lymphomas.
Gomez-Gelvez JC; Smith LB
Arch Pathol Lab Med; 2015 Oct; 139(10):1205-10. PubMed ID: 26414463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
